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Editorial
On 15.5.2009 the President of the Republic submitted
the Finnish Parliament a government bill for a law re-
lating to the new Medicines Agency, Lääkealan turval-
lisuus- ja kehittämiskeskus: this will be an administra-
tive Act. The Ministry of Social Affairs and Health had
previously made a decision to relocate the Agency to
Kuopio. I started in my post as the Director General at
the National Agency for Medicines in February in the
middle of reorganisation. It appears that I started my
work in the eye of the storm, as the editorial of TABU
described the situation of the pharmaceutical adminis-
tration last autumn.
The aim of the government bill is to reorganise the
administration of pharmaceutical service in such a way
that the pharmaceutical expertise in the administrative
field of the Ministry of Social Affairs and Health
would be concentrated in the new Agency.
The objectives are to improve the role of pharma-
ceutical expertise in the social and healthcare service
system, improve the process of marketing authorisa-
tions and pharmaceutical regulation, ensure the avail-
ability of medicines nationally, improve the safety of
medicinal products and medications and also to con-
tribute to the research and development of the pharma-
ceutical field. One of the objectives is also to arrange
for a national evaluation of the therapeutic and eco-
nomic value of medicines and to develop influence of
the pharmaceutical field internationally and within the
EU.
The Ministry of Social Affairs and Health requested
statements from the stakeholder groups and held a
consultation on the options in April. The majority of
the written statements considered a reorganisation of
the pharmaceutical service justified. While amalgamat-
ing the duties relating to marketing authorisation and
regulatory affairs into the same organisation with re-
search and development, emphasis was given to safe-
guarding the independence of the various tasks and fi-
nancing.
It is proposed that the main responsibilities of the
new Medicines Agency should include responsibilities
involved with marketing authorisations and regulatory
affairs, pharmaceutical research and development, and
the generation and distribution of pharmaceutical ex-
pertise in order to improve the impact of pharmaceuti-
cal service and therapies.
According to the government bill the new Agency
will improve public health and safety by regulating
medicinal products and medically used tissues and by
developing the pharmaceutical field. Research and de-
velopment activities will also support decision-making
concerning medicinal products in society. The Agency
intends, for example, to carry on pharmaco-political
and pharmaco-economical research and to improve co-
operation within research and development in the
pharmaceutical field. In addition to guaranteeing the
safety of medicinal products, the Agency will also guar-
antee the safety of medically used tissues. The reorgani-
sation would, however, mean that responsibilities asso-
ciated with medical devices would be borne by the Na-
tional Supervisory Authority for Welfare and Health
(Valvira). The new Agency will maintain close co-oper-
ation with pharmaceutical entrepreneurs and stake-
holder groups.
The government bill will provide a framework for
the new organisation and will direct the development
of new operators in the pharmaceutical field. In the de-
velopment of operational models and organisational
structures for the new Agency attention will be paid to
the impartiality of the responsibilities involved in mar-
keting authorisations and regulatory affairs and the in-
dependence of scientific research. It is also important
that the working methods are formulated in such a
way that the Agency will be able to serve the pharma-
ceutical field and health care successfully in accordance
with the aims of the reorganisation.
The National Agency for Medicines (NAM) in its
present form has devoted significant amounts of its ex-
pertise to the preparation of this government bill. Top
know-how is available at NAM to promote the reor-
ganisation, which requires open-mindedness, courage
and expertise, not forgetting solidarity which is also re-
quired. Reforms provide a number of opportunities,
but they also involve risks. Resources should be allo-
cated to the careful development of this reform, to
minimise risks and, above all, to ensure that pharma-
ceutical regulation is safeguarded in a very challenging
and multifaceted situation of change.
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Reporting an adverse incident
The premiss of a report on an ad-
verse incident is constituted by an
association with a medical device
which causes or could cause seri-
ous harm to the patient, person-
nel or another individual. For the
system to operate completely ef-
fectively it is required that ad-
verse incidents should be recog-
nised and reported. Users of de-
vices and accessories are keys to
the system. Without them, infor-
mation about incidents would
not be passed on. Reports on ad-
verse incidents are submitted to
NAM by the users of devices,
who should also inform the rep-
resentatives of the manufacturers
of the devices. A device and the
associated materials involved in
the adverse incident should be
maintained unchanged until the
manufacturer has had an oppor-
tunity to establish and document
the incident. In the present Euro-
pean vigilance system, the re-
sponsibility for resolving the inci-
dent lies with the manufacturer.
A report on the adverse incident
and on the measures intended
and taken is submitted by the
manufacturer to the authorities
of the country where the incident
occurred. 
Both users and manufacturers
of devices should follow the regu-
lations stipulated for reporting of
adverse incidents (Administrative
Regulations by NAM 4/2005 and
5/2005). Despite the regulations
in force it still appears to be diffi-
cult to recognise and submit a re-
port on an adverse incident. To
make it easier to recognise ad-
verse incidents NAM sent a circu-
lar letter to healthcare units in
October 2008 reminding them
about their responsibility to re-
port any incidents they detect and
giving concrete examples of ad-
verse incidents on which reports
should be made. It was also em-
phasised that the purpose of re-
porting is to promote the safety
of medical devices and that there
was no intention of trying to find
culprits. Health care units have in
recent years introduced voluntary
internal reporting systems, which
for their part promote the recog-
nition of adverse incidents as well
as the reporting of these to the
authorities. Reminders, improved
motivation, regulations and train-
ing are needed in future as well.
Both professional users and de-
vice manufacturers are still re-
porting only a proportion of inci-
dents to NAM. Fig. 1 shows the
number of reports on incidents
submitted by users in relation to
reports by device manufacturers
relative to adverse incidents that
have taken place in Finland. Irre-
spective of the number of reports
submitted annually, the propor-
tion of reports submitted by users
is about half of those submitted
by device manufacturers. On ex-
amining the Figure it should be
noted that not even then do all
manufacturers report all the ad-
The National Agency for Medicines supervises and promotes the safe use of medical devices. This 
work includes the processing of reports on adverse incidents and the reviewing of the associated 
incidents together with the manufacturers and users of the devices. Reporting of adverse incidents is
a legal requirement. Such reports are received from users, manufacturers, and other responsible 
national bodies. NAM compiles the reports received from various sources and forms an overall view 
of the incidents. Information received is subsequently used for preventing adverse incidents from 
occurring. Information about incidents detected in one EEA member state will where necessary even
be made use of in other member states. Information put together from reports on adverse incidents
can be examined not only with regard to safety aspects but also in the light of ensuring a faultless 
reporting system.
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verse incidents they detect. Every
adverse incident occurring in Fin-
land should be reported by both
the user and the manufacturer.
Another graph concerning re-
porting activity is shown in Fig.
2, in which the number of re-
ports received from users is ex-
amined monthly over a period of
three years. Following the letter
of reminder sent in October
2008, an increase in reporting
activity was seen for some
months and was in fact three
times that in comparison with
the previous level.
The number of reports on
adverse incidents
The annual total number of re-
ports has increased continuously
(Fig. 3). The growth cannot be
interpreted as a sign of deterio-
rating product safety or of an in-
crease in user faults; it is rather a
sign of development of informa-
tion flow, of the reporting system
and of the culture of safety. The
increase in reports on adverse in-
cidents applies in nearly all re-
porter groups, i.e. professional
users, Finnish and foreign manu-
facturers and authorities.
Fig. 3 shows those that have
submitted reports as users (U),
Finnish manufacturers (M), for-
eign manufacturers (M2), author-
ities in the European Economic
Area (EU CA) and other authori-
ties (Other CA). The graph only
shows the proportion of reports
concerned with devices in use in
Finland. In addition to these re-
ports NAM also receives reports
from authorities about products
not marketed in Finland. In 2008
the total number of reports con-
cerning adverse incidents pro-
cessed by NAM amounted to
nearly 1 000, about two thirds of
Fig. 1. The number of adverse incidents reported in
Finland annually. Reports are made by device manu-
facturers (the darker column) and by users. The line in
the graph depicts the relationship between the two
types of reports (percentage scale on the right).
Fig. 2. The number of reports submitted by users
monthly during 2006–2009.
Fig. 3. The development of numbers of reports in the
past five years (reports concerning Finland).
Fig. 4. The relative proportion in percentage of re-
ports on adverse incidents associated with the differ-
ent groups of devices. The distribution highlighted in
a darker colour is the mean percentage in 2000 to
2007 and the one in a lighter colour is the distribu-
tion in 2008.
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Single use devices
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Assistive products for persons with disability
Diagnostic and therapeutic radiation devices
which concerned devices and ac-
cessories in use in Finland.
Accurate conclusions cannot
be drawn about the number of
reports on adverse incidents,
partly because several reports
may have been submitted on one
and the same incident. Initially
the report on an adverse incident
is typically received from the user
or the manufacturer. As reports
from both of these sources are
relevant for obtaining an overall
picture, the missing report is re-
quested where necessary. Reports
received from foreign manufac-
turers are often also followed by
a report from the authorities
with the aim of informing the
other member states. 
The number of reports is in-
creased by reports required of
the manufacturer concerning any
separate remedial measure that
the manufacturer needs to take
after having examined the inci-
dent, e.g. recall of the product
from the market.
Product groups associated
with adverse incidents
In order to facilitate the process-
ing of common data, standard-
ised grouping of devices has been
in use in Europe for quite a long
time (EN ISO 15225 – Specifica-
tion for a nomenclature system
for medical devices for the pur-
pose of regulatory data ex-
change). On examining the re-
ports on adverse incidents ac-
cording to groups of devices,
four groups emerge: products for
single use, electrical and mechan-
ical medical devices, sample mea-
suring instruments (i.e. IVD
products) and non-active im-
plants (Fig. 4). Considering the
number of products on the mar-
ket, the groups of devices based
on the standard are not equally
big. Consequently, the group of
electrical and mechanical devices,
for example, has a wide repre-
sentation in the reports on ad-
verse incidents. In this group the
devices typically representing ad-
verse incidents include patient
monitoring equipment and defib-
rillators. Adverse incidents asso-
ciated with disposable health
care devices have consisted main-
ly, for example, of mechanical
defects developing in the use of
catheters. Generally, these inci-
dents are serious when parts of
the device remain in the body.
Adverse incidents associated with
non-active implants have mostly
concerned orthopaedic implants,
especially endoprostheses. NAM
is able to monitor the quality of
endoprostheses with the help not
only of the reports on adverse in-
cidents but also of the data con-
tained in the implant register.
According to Fig. 4, the divi-
sion of reports on adverse inci-
dent in 2008 into the different
groups of devices corresponds
relatively well to the long-term
medium. The biggest changes can
be seen in the reports associated
with imaging devices and re-
usable devices, the relative pro-
portion of which has doubled.
Defibrillators deserve a special
mention under the general head-
ing of electrical and mechanical
devices.  External defibrillators
are used both in the resuscitation
of patients and in rhythm trans-
fers whereas internal defibrillators
are life-maintaining devices since
they impose a beat pacing the
heart each time they detect a
rhythm that needs defibrillation.
Defibrillators that fail to function
may be fatal to patients. During
the past five years regularly about
30 to 34 adverse incidents associ-
ated with the use of defibrillators
have been reported every year. A
little more than half of these con-
cern external defibrillators. A typ-
ical adverse incident is created by
a functional defect in semi-auto-
matic defibrillators which have
come into common use, in which
case the device does not detect the
rhythm that needs defibrillation.
Resuscitation especially in an
acute situation under all circum-
stances requires high reliability
from a defibrillator.
Causes of adverse incidents
Fig. 5. shows the distribution of
causes of serious adverse inci-
dents relative to Finland in 2008.
There is no significant variation
in the distribution in comparison
with previous years. The majori-
ty of adverse incidents are caused
by the device becoming defective
after introduction into use or be-
ing defective already prior to use.
The defects can be either me-
chanical or electrical. The pro-
portion of failures owing to use
error is in the range of 10%.
Safety information
Medical device safety notice
(MDSN) are one method by
which NAM aims to prevent the
development of new adverse inci-
dents. As a rule, safety reports
disclose several reports on ad-
verse incidents associated with
the use of one and the same type
of device. An average of one to
two reports are published annu-
ally. The most recent safety re-
port published in the beginning
of the year concerns the connec-
tions of enteral feeding tubes. All
medical device safety reports
published are found on the web-
site of NAM in Finnish and
Swedish. MDSN reports are also
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Fig. 5. The distribution of causes
of serious adverse incidents that
have occurred in Finland in 2008.
Other
Use error
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Defect before
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found on the official websites of
authorities of other member
states, e.g. the UK Medicines and
Healthcare Products Regulatory
Agency, MHRA.
Collaboration between
authorities
The system of reporting of ad-
verse incidents has become estab-
lished and works well. As part of
their routine, responsible device
manufacturers send information
about the remedial measures to
be taken as a result of detection
of an adverse incident to the au-
thorities of all those countries
where the device is marketed.
Should the manufacturer for any
reason not inform other member
states about remedial measures,
the responsible authority can
submit the relevant information
to the authorities of other mem-
ber states. These are called re-
ports of National Competent Au-
thority (NCAR) and are promul-
gated by means of the use of a
common form. In Fig. 3. the pro-
portions of reports from authori-
ties are shown in yellow (EU CA
and Other CA).
The number of reports from
authorities totalled 308 in 2008.
The number of reports submitted
by the authorities of the various
member states together with the
associated references are avail-
able on the public website of the
European Commission.
New regulations about reports
on adverse incidents
The EU Commission has issued
regulations about reporting on
adverse incidents in its recent
Guidelines on a Medical Devices
Vigilance System (MEDDEV
2.12/1 Rev 5.5.). These will as
and when appropriate replace
NAM’s earlier guidelines, and in
comparison with the earlier pro-
cedure the amendments include
accounting for misuses and em-
bodying them in the manufactur-
ers’ reporting system together
with new and stricter time limits
for submitting reports. Up until
now a report has been required
according to the seriousness of
the case within either 10 or 30
days, but the new regulation in-
cludes a new 48-hour time limit
for the incidents that are very se-
rious and which from the public
health point of view call for ur-
gent handling.
Adverse incident reporting by
entrepreneurs
A new government bill on med-
ical devices and accessories is at
present awaiting processing. One
of the new issues dealt with in
the government bill is the liabili-
ty of the entrepreneur to report
any adverse incidents. An entre-
preneur in this sense signifies, for
example, an importer, distribu-
tor, installer or other handler in
the chain in which the device or
accessory is transferred from the
manufacturer to the end user. In
practice this means improved de-
tectability of hazard-causing inci-
dents or device defects and prob-
ably also an increase in the num-
ber of reports to be processed.
Links associated with the
subject
Forms and guidelines for medical de-
vice adverse incident reporting to
NAM:
http://www.laakelaitos.fi/medical_
devices/incident_reporting
The Commission guideline MEDDEV
2.12/1 rev 5: Medical Devices
Vigilance System: 
http://ec.europa.eu/enterprise/medical_
devices/meddev/meddev_en.htm
The authorities’ websites and other
contact information:
http://ec.europa.eu/enterprise/medical_
devices/ca/list_ca.htm
Act on Medical Devices
– a motion to the Ministry of Social
Affairs and Health on 29.9.2008:
http://www.laakelaitos.fi/laitteet_ja_
tarvikkeet
Conclusion
• The adverse incident repor-
ting system has been success-
fully harmonised and establis-
hed in the member states of
the European Economic Area.
Data relevant to the incidents
and statistics involved have
been extensively accumulated
over several years. 
• Processing of individual
adverse incidents involving
medical devices is always con-
fidential, but utilisation of the
filtered information needs to
be improved in future in order
to prevent adverse incidents.
Attempts should be made
through feedback and commu-
nication to motivate users of
medical devices and accessori-
es towards improving the sub-
mitting of reports.
• Continuous increase in the
total number of reports of
adverse incidents under pro-
cessing presents a challenge.
The introduction of electronic
forms for reporting accelerate
the processing and improve
the usage of the system.
As the National Agency for
Medicines (NAM) will cease
to operate and a new Medi-
cines Agency will be estab-
lished, it is proposed that re-
sponsibilities relating to med-
ical devices be transferred to
the National Supervisory Au-
thority for Welfare and Health
(Valvira) of the Ministry of
Social Affairs and Health.
Conclusions
• Both traditional and cox-2 selective NSAIDs slightly increase the risk of cardiovascular events.
• The most clear-cut evidence is that involving rofecoxib.
• The cardiovascular risk for both rofecoxib and celecoxib, and probably all NSAIDs, is dose-dependent.
• The risk of high-dose celecoxib is similar to that of traditional NSAIDs. On the other hand, the risk of
low-dose celecoxib, especially when used once daily, appears to be similar to that of non-users.
• The increased cardiovascular risk of all NSAIDs is, at least in part, explained by impaired kidney 
function, i.e. sodium retention, deterioration of cardiac insufficiency, and increase in blood pressure.
• Compared with traditional NSAIDs, selective cox-2 inhibitors may bring additional risk in that they 
exert prothrombotic effects that increase ischemic cardiovascular events, especially cardiac infarctions. This
is most likely in situations where cox-2 expression of the intima of the blood vessel is increased 
(e.g. vascular surgery).
• Combining low dose aspirin with a coxib may decrease cardiovascular risk but in turn increase
gastrointestinal risk.
• The adverse cardiovascular effects of NSAIDs can be decreased by intermittent use and by minimizing
treatment periods and doses.
• The proper use of NSAIDs requires joint evaluation of both the cardiovascular and gastrointestinal risks
of the patient.
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Summary
The cardiovascular adverse effects of coxibs 
- time for interim evaluation
Nonsteroidal antiinflammatory drugs (NSAIDs) were associated with circulatory prothrombotic events
in 2004 when the cox-2 selective rofecoxib was withdrawn from the market because of increased risk
of cardiovascular events. The cardiovascular problems were explained by the following: 1) the cardio-
vascular adverse effects of rofecoxib were only an artefacat  and due to the aspirin-like protective
mechamism of the comparator drug naproxen on the cardiovascular system, 2) the adverse effects of
rofecoxib were non-specific and not related to cox-2 -selectivity, 3) the cardiovascular problems were
due to the cox-2 selectivity of rofecoxib, and thus is a class effect of all coxibs, and 4) all NSAIDs can
cause cardiovascular harm. At the moment, there is evidence to support any of these hypotheses. To
find the truth, one has to go through controlled randomized studies including at least 145 000 pa-
tients and observational studies consisting of 3,5  million patients. Conclusions of this article are
based on the major controlled studies on coxibs and the latest meta-analyses of the controlled and
epidemiological studies, as well as some basic research findings on NSAID pharmacology.
